Genome Of Hospital Superbug Sequenced
Posted on: Wednesday, 7 May 2008, 10:49 CDT
The genome of a newly-emerging superbug, commonly known as Steno, has just been sequenced. The results reveal an organism with a remarkable capacity for drug resistance. The research was carried out by scientists at the Wellcome Trust Sanger Institute near Cambridge and the University of Bristol.Understanding the genome of this bacterium will help researchers discover how to deal with this particularly resistant organism. The paper will be published in Genome Biology.
Dr Matthew Avison from the University of Bristol, and senior author on the paper said: “This is the latest in an ever-increasing list of antibiotic-resistant hospital superbugs. The degree of resistance it shows is very worrying. Strains are now emerging that are resistant to all available antibiotics, and no new drugs capable of combating these ‘pan-resistant’ strains are currently in development.”
Pan-resistant Steno infections are at least as hard to treat as MRSA and C.diff infections. But although it is common in the environment, Steno infections are rarer than MRSA and C.diff infections and are exclusively hospital-acquired.
Steno flourishes in moist environments, such as around taps and shower heads, and can be transferred to patients . It is distinct in the way it causes infection and can only get into the body via devices such as catheters or ventilation tubes that are left in place for long periods of time. Long-dwelling catheters are used most often for seriously ill patients and some undergoing chemotherapy.
Steno can stick to the catheter and grow into a ‘biofilm’. When the catheter is next flushed, the Steno biofilm can enter the patient’s bloodstream. If their immune system is impaired (which is often the case in the seriously ill and those undergoing chemotherapy) the organism can multiply and cause septicaemia. The gravity of this situation has been underlined by the new research, since these patients will be treated with antibiotics against which Steno is largely resistant.
There are approximately 1,000 reports of Stenotrophomonas maltophilia (Steno) blood poisoning in the UK each year, with a mortality rate of about 30%. The organism is also found in the lungs of many adults with cystic fibrosis, and causes ventilator-associated pneumonias, particularly in elderly intensive-care patients.
The key questions that need to be addressed are: How does Steno stick to surfaces like catheters and ventilator tubes" How does it form biofilms and so survive attempts to decontaminate and clean" Why is it resistant to antibiotics"
Dr Lisa Crossman from the Sanger Institute and first author on the paper explained how the research might address these questions: “The genome sequence should help us to combat these properties . For example, if we know which proteins cause it to stick to surfaces, we could try to develop biochemical compounds that interfere with this interaction. If we understand its antibiotic resistance mechanisms, we might be able to design inhibitors that block them.”
While Steno infections are still relatively uncommon, they are on the increase. Furthermore, there are two other organisms that cause similar types of infections, but are more common.
Dr Avison added: “Genome sequences for these two also exist, and so now we can look at what they all have in common genetically that might explain why they are so resistant to antibiotics.”
---
Image 1: A Steno bacterium dividing. Photo by Matthew Avison
Image 2: Comparison of the genome of Steno (outside) and its relatives that attack plants. Photo by Lisa Crossman
---
On the Net:
University of Bristol
Wellcome Trust Sanger Institute
Genome Biology
Related Articles
- New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
- CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
- Blue Light Can Destroy Antibiotic-resistant Staph Infection
- Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
- Research and Markets: Antibiotics and Drug Resistance 2007 - Drug Innovation and the Strategy to Combat Antibiotic Resistance Mechanisms
- Main Line Health Hospitals Select Premier Healthcare Alliance to Better Protect Patients Against Healthcare Associated Infections, Antibiotic Overuse
- Many Diagnostics (E.G., Phenotypic Tests, Molecular Tests) Are Now Available to Detect Pathogens and Determine Antibiotic Susceptibility - Identifying Drug-Resistant Bacterial Infections
- New Antibiotic Aimed at Resistant Germs
- Chairman of Patient Safety Technologies Named to Center for Patient Safety Research and Practice at the Brigham and Women's Hospital and Harvard Medical School
- Nektar Announces Inhaled Amphotericin B Product in Human Clinical Trials for Preventing Fatal Pulmonary Fungal Infections in Immunosuppressed Patients
User Comments (0)



RSS Feeds